TORONTO, Nov. 4, 2019 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America, announces that Mark Monaghan has resigned as a director of the
Company and that Deborah Rosati FCPA, FCA, ICD.D has been appointed
effective immediately to the Board of Directors of the Company. Ms.
Rosati has over 30 years of experience in leading and managing high
growth companies and joins the Board, effective immediately.
Deborah Rosati is an accomplished
corporate director, entrepreneur and FCPA with more than 30 years
of experience, including in consumer, cannabis, private equity and
venture capital, and has advised over 20 private companies on
business strategy and financial growth. Deborah is a past Board
member and Chair of the Audit Committee at MedReleaf Corp.
(acquired by Aurora Cannabis), the Founder and CEO of Women Get On
Board, a member-based company that connects, promotes and empowers
women to corporate boards, and is the recipient of multiple finance
and leadership awards.
Deborah's extensive audit and governance experience includes
positions as past Chair of the Audit Committee at Sears Canada
Inc., a Member of the Department Audit Committee at Correction
Services Canada, and at NexJ Systems Inc. where she was a Board
member and Chair of the Audit Committee.
"We are very pleased to welcome Deborah. Her experience in
finance, corporate strategy, mergers and acquisitions, and
governance will be a tremendous asset for the Company. As we
continue to expand our operations and execute on our business
strategy, Deborah's appointment to our Board is a valued addition,"
said Alvaro Torres, Khiron CEO and
Director. "We would also like to thank Mark for his many
contributions to Khiron since its founding in 2017 when he led the
seed capital round to start the Company. Mark has seen Khiron grow
from just an idea to the leading brand in Latin America in the emerging medical cannabis
industry. His strategic advice has been invaluable, and we look
forward to maintaining that relationship with him as a key advisor
going forward. We wish him the best in his future
endeavors."
Mark Monaghan commented, "I am
extremely proud of what Khiron has accomplished over the past 3
years and I leave the Company well positioned, and well funded to
take advantage of its vast market opportunity, and to be a leading
global brand. Now is the right time to transition off the Board.
I'm confident that Khiron is prepared to continue its success as it
attracts a high caliber, independent director in Deborah Rosati."
About Khiron Life Sciences Corp.
Khiron Life Sciences
Corp. is positioned to be the dominant integrated cannabis company
in Latin America. Khiron has core
operations in Latin America and is
fully licensed in Colombia for the
cultivation, production, domestic distribution, and international
export of both tetrahydrocannabinol (THC) and cannabidiol (CBD)
medical cannabis. The company delivers best in class regulatory
compliance, has the first approved set of CBD cosmetic products on
shelf in Colombia, and is currently facilitating testing to
meet and surpass all license requirements for commercial cannabis
derived products.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Cautionary Notes
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
Further information in respect of the Company can be found at
www.khiron.ca.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-appoints-veteran-independent-director-deborah-rosati-fcpa-fca-icdd-300950467.html
SOURCE Khiron Life Sciences Corp.